Tipo
Research/project funding
Posted on
Funding Opportunity RFA-AI-24-076 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support preclinical activities for the development of safe and effective long-acting/sustained release (LA/SR) technologies for prevention and treatment of HIV and HIV-associated tuberculosis (TB), hepatitis B (HBV) and hepatitis C (HCV), and to ultimately advance these products toward submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). Solicited LA/SR products will have demonstrated strong rationale, competitive advantage, and effectiveness in appropriate non-clinical or animal models at intermittent dosing from either a single administration (injection, topical, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.).